CF 1743

Drug Profile

CF 1743

Alternative Names: CF-1743

Latest Information Update: 14 Jul 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rega Institute for Medical Research; University of Wales
  • Developer FermaVir Pharmaceuticals
  • Class Antivirals; Nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes zoster

Most Recent Events

  • 14 Jul 2009 Discontinued - Preclinical for Herpes zoster in USA (Topical)
  • 20 Sep 2007 FermaVir Pharmaceuticals has been acquired by Inhibitex
  • 20 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top